Nuwellis, Inc. (NUWE) stock forecast & analysis
1 analysis in the last 30 days. Latest: .
Market Scanner’s AI analysis of Nuwellis, Inc. (NUWE), updated July 2026: Nuwellis's Aquadex SmartFlow expansion and study acceptance contrasted with bearish technical indicators and negative margins.
Summary
Nuwellis's Aquadex SmartFlow expansion and study acceptance contrasted with bearish technical indicators and negative margins.
Recent analyses for NUWE covered the expansion of its Aquadex SmartFlow system into the pediatric sector and the acceptance of a study supporting its Aquadex Ultrafiltration Therapy. The company also announced preliminary second-quarter revenue growth and discussed its strategy for value creation. However, technical indicators suggest a bearish long-term trend, with the stock trading below its 50-day and 200-day SMAs, and the MACD indicating bearish momentum. The company's financial fundamentals show negative profit and operating margins.
NUWE news & sentiment
News reports highlighted positive developments for NUWE, including product expansion and study acceptance, alongside preliminary revenue growth. Social media sentiment data was unavailable.
NUWE technical picture
The stock's price action is below its 50-day and 200-day SMAs, indicating a bearish long-term trend. Short-term momentum is also downward, as suggested by the 10-day EMA and MACD readings. RSI sits near neutral levels, while MFI shows significant buying pressure. ATR indicates moderate volatility.
Fundamentals
Nuwellis's recent financial reports showed modest year-over-year quarterly revenue growth alongside negative profit and operating margins. The company's valuation metrics, including P/E ratios, also indicated a negative earnings outlook based on trailing twelve months data.
Factors discussed — upside
- Expansion of Aquadex SmartFlow system into the pediatric sector in Wisconsin.
- Study supporting alternative anticoagulation strategy for Aquadex Ultrafiltration Therapy accepted by Frontiers in Pediatrics.
- Preliminary second-quarter revenue results showing double-digit growth.
- New CEO discussing company's strategy for sustainable value creation.
- Money Flow Index (MFI) at 99.58, suggesting significant buying pressure.
Factors discussed — risks
- Stock price below 50-day and 200-day Simple Moving Averages.
- 10-day Exponential Moving Average significantly below SMAs, suggesting strong short-term downward momentum.
- MACD below zero, indicating bearish momentum.
- Negative profit margin of -2.17%.
- Negative operating margin of -1.90%.
- Product Expansion
- Therapeutic Validation
- Financial Performance
- Technical Indicators
Summary updated .
Analyses
Recent NUWE.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Nuwellis, Inc.?
- The bull case for Nuwellis centers on the expansion of its Aquadex SmartFlow system into the pediatric sector and the acceptance of a study supporting its Aquadex Ultrafiltration Therapy. The company also reported preliminary double-digit revenue growth for the second quarter and discussed its strategy for value creation, supported by significant buying pressure indicated by the Money Flow Index.
- What are the risks for Nuwellis, Inc.?
- Risks for Nuwellis include a bearish long-term technical trend, with the stock price below key moving averages and bearish momentum indicated by the MACD. The company also faces headwinds from negative profit and operating margins, alongside a high Money Flow Index that contradicts the bearish technical indicators.
- Is Nuwellis, Inc. bullish or bearish?
- Recent AI analyses of Nuwellis, Inc. examined factors on both sides. Discussed upside: The bull case for Nuwellis centers on the expansion of its Aquadex SmartFlow system into the pediatric sector and the acceptance of a study supporting its Aquadex Ultrafiltration Therapy. The company also reported preliminary double-digit revenue growth for the second quarter and discussed its strategy for value creation, supported by significant buying pressure indicated by the Money Flow Index. Discussed risks: Risks for Nuwellis include a bearish long-term technical trend, with the stock price below key moving averages and bearish momentum indicated by the MACD. The company also faces headwinds from negative profit and operating margins, alongside a high Money Flow Index that contradicts the bearish technical indicators. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Nuwellis, Inc.?
- News reports highlighted positive developments for NUWE, including product expansion and study acceptance, alongside preliminary revenue growth. Social media sentiment data was unavailable.
- Bundles used
- gemini-low-v2
Sign in to read every NUWE.US report in the library
Each analysis includes the full reasoning, dissent, and decision rationale from the structured AI pipeline.